Venus Medtech (Hangzhou) Inc.
HKEX:2500.HK
5.62 (HKD) • At close July 23, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) HKD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q2 | 2018 Q1 | 2017 Q4 | 2017 Q2 | 2017 Q1 | 2016 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 117.882 | 117.882 | 127.805 | 127.805 | 98.248 | 98.248 | 104.983 | 58.318 | 58.318 | 58.318 | 28.837 | 28.837 | 28.837 | 4.541 | 4.541 | 4.541 |
| Kosten van de omzet
| 23.904 | 23.904 | 27.181 | 27.181 | 23.337 | 23.337 | 22.895 | 9.652 | 9.652 | 9.652 | 4.092 | 4.092 | 4.092 | 0.769 | 0.769 | 0.769 |
| Brutowinst
| 93.978 | 93.978 | 100.625 | 100.625 | 74.912 | 74.912 | 82.088 | 48.666 | 48.666 | 48.666 | 24.745 | 24.745 | 24.745 | 3.772 | 3.772 | 3.772 |
| Brutowinstmarge
| 0.797 | 0.797 | 0.787 | 0.787 | 0.762 | 0.762 | 0.782 | 0.834 | 0.834 | 0.834 | 0.858 | 0.858 | 0.858 | 0.831 | 0.831 | 0.831 |
| Onderzoek- en ontwikkelingskosten
| 115.1 | 115.1 | 147.358 | 147.358 | 153.568 | 153.568 | 110.158 | 50.133 | 50.133 | 50.133 | 26.194 | 26.194 | 26.194 | 29.34 | 29.34 | 29.34 |
| Algemene en administratieve kosten
| 37.947 | 37.947 | 38.947 | 38.947 | 60.817 | 60.817 | 27.373 | 49.402 | 49.402 | 49.402 | 8.161 | 8.161 | 8.161 | 2.809 | 2.809 | 2.809 |
| Verkoop- en marketingkosten
| 71.283 | 71.283 | 78.956 | 78.956 | 68.513 | 68.513 | 61.679 | 31.142 | 31.142 | 31.142 | 16.716 | 16.716 | 16.716 | 8.981 | 8.981 | 8.981 |
| Verkoop-, algemene en administratieve kosten
| 104.715 | 104.715 | 122.417 | 122.417 | 127.538 | 127.538 | 90.843 | 80.544 | 80.544 | 80.544 | 24.877 | 24.877 | 24.877 | 11.79 | 11.79 | 11.79 |
| Overige kosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.297 | -2.297 | -2.297 | 47.296 | 47.296 | 47.296 | 1.113 | 1.113 | 1.113 |
| Bedrijfskosten
| 277.941 | 277.941 | 270.202 | 270.202 | 534.093 | 534.093 | 196.091 | 128.379 | 128.379 | 128.379 | 98.367 | 98.367 | 98.367 | 42.242 | 42.242 | 42.242 |
| Bedrijfsresultaat
| -124.732 | -124.732 | -169.15 | -169.15 | -217.18 | -217.18 | -118.913 | -93.122 | -93.122 | -93.122 | -74.075 | -74.075 | -74.075 | -38.631 | -38.631 | -38.631 |
| Bedrijfsresultaat ratio
| -1.058 | -1.058 | -1.323 | -1.323 | -2.211 | -2.211 | -1.133 | -1.597 | -1.597 | -1.597 | -2.569 | -2.569 | -2.569 | -8.507 | -8.507 | -8.507 |
| Totaal overige inkomsten en kosten netto
| -57.769 | -57.769 | -16.02 | -16.02 | -237.789 | -237.789 | -4.29 | -2.264 | -2.264 | -2.264 | -0.83 | -0.83 | -0.83 | -0.732 | -0.732 | -0.732 |
| Inkomen voor belasting
| -182.501 | -182.501 | -185.17 | -185.17 | -454.969 | -454.969 | -123.203 | -95.386 | -95.386 | -95.386 | -74.905 | -74.905 | -74.905 | -39.362 | -39.362 | -39.362 |
| Inkomen voor belasting ratio
| -1.548 | -1.548 | -1.449 | -1.449 | -4.631 | -4.631 | -1.174 | -1.636 | -1.636 | -1.636 | -2.598 | -2.598 | -2.598 | -8.668 | -8.668 | -8.668 |
| Belastingkosten
| 1.08 | 1.08 | 2.062 | 2.062 | 13.782 | 13.782 | 3.369 | -0.195 | -0.195 | -0.195 | 0.225 | 0.225 | 0.225 | 0.125 | 0.125 | 0.125 |
| Nettowinst
| -176.783 | -176.783 | -175.094 | -175.094 | -428.883 | -428.883 | -99.967 | -95.191 | -95.191 | -95.191 | -75.13 | -75.13 | -75.13 | -39.487 | -39.487 | -39.487 |
| Nettowinstmarge
| -1.5 | -1.5 | -1.37 | -1.37 | -4.365 | -4.365 | -0.952 | -1.632 | -1.632 | -1.632 | -2.605 | -2.605 | -2.605 | -8.696 | -8.696 | -8.696 |
| WPA (Winst Per Aandeel)
| -0.4 | -0.4 | -0.4 | -0.4 | -0.98 | -0.98 | -0.23 | -0.31 | -0.31 | -0.31 | -0.19 | -0.19 | -0.19 | -0.1 | -0.1 | -0.1 |
| Verwaterde WPA
| -0.4 | -0.4 | -0.4 | -0.4 | -0.98 | -0.98 | -0.23 | -0.31 | -0.31 | -0.31 | -0.19 | -0.19 | -0.19 | -0.1 | -0.1 | -0.1 |
| EBITDA
| -104.365 | -104.365 | -147.649 | -147.649 | -199.534 | -199.534 | -96.063 | -85.895 | -85.895 | -85.895 | -71.564 | -71.564 | -71.564 | -37.052 | -37.052 | -37.052 |
| EBITDA ratio
| -0.885 | -0.885 | -1.155 | -1.155 | -2.031 | -2.031 | -0.915 | -1.473 | -1.473 | -1.473 | -2.482 | -2.482 | -2.482 | -8.159 | -8.159 | -8.159 |